miR-155在弥漫性大B细胞淋巴瘤预后预测中的应用价值  

miR-155 in predicting prognosis of diffuse large B-cell lymphoma

作　　者：李星[1] 石昊[2] LI Xing;SHI Hao(Department of Oncology and Hematology,Head and Neck Surgery,Yan'an People's Hospital,Shaanxi Yan'an 716000,China;Department of Otolaryngology,Head and Neck Surgery,Yan'an People's Hospital,Shaanxi Yan'an 716000,China)

机构地区：[1]延安市人民医院肿瘤血液科,陕西延安716000 [2]延安市人民医院耳鼻咽喉头颈外科,陕西延安716000

出　　处：《现代肿瘤医学》2021年第2期307-311,共5页Journal of Modern Oncology

摘　　要：目的:探讨miR-155在弥漫性大B细胞淋巴瘤预后预测中的应用价值。方法:选取我院收治的120例弥漫性大B细胞淋巴瘤作为研究对象,采用qRT-PCR检测所有患者癌组织miR-155的相对表达水平,根据miR-155的表达水平将所有患者分成miR-155高表达组(n=72)和miR-155低表达组(n=48),比较两组患者的临床病理资料、生存率,采用Cox比例风险回归模型对弥漫性大B细胞淋巴瘤患者的预后进行单因素和多因素分析,并分析miR-155对弥漫性大B细胞淋巴瘤细胞增殖和迁移能力的影响。结果:miR-155高表达组患者结外侵犯比例显著高于miR-155低表达组(P<0.05);miR-155高表达组患者3年无进展生存率(29.2%)及总体生存率(40.3%)均显著低于miR-155低表达组(81.3%和83.3%);单因素和多因素分析结果均显示miR-155表达水平是DLBCL无进展生存期和总体生存期的影响因素;miR-155低表达组细胞划痕愈合速度(0.53±0.04)显著低于对照组细胞(1.0±0.03)(P<0.05),miR-155低表达组细胞在培养的3、4 d的吸光度值显著低于对照组(0.38±0.01 vs 0.56±0.03;0.56±0.02 vs 0.76±0.02)(P<0.05)。结论:弥漫性大B细胞淋巴瘤患者的miR-155表达水平显著影响患者的预后,其可能机制是通过影响弥漫性大B细胞淋巴瘤细胞的增殖和迁移能力,提示miR-155可能是弥漫性大B细胞淋巴瘤新的和可靠的预后生物标志物,值得进一步深入研究。Objective:To evaluate the value of miR-155 in predicting prognosis of diffuse large B-cell lymphoma.Methods:120 cases of diffuse large B-cell lymphoma in our hospital were selected as the subjects.The relative expression of miR-155 in all patients was detected by qRT-PCR.According to the expression level of miR-155,all patients were divided into two groups:high expression of miR-155(n=72)and low expression of miR-155(n=48).The clinicopathological data and survival rate of the two groups were compared.The Cox proportional hazard regression model was used to analyze diffuse large B patients.The prognosis of patients with cell lymphoma was analyzed by single factor and multi-factor,and the effect of miR-155 on the proliferation and migration of diffuse large B-cell lymphoma cells was analyzed.Results:The percentage of extranodal invasion in patients with high expression of miR-155 was significantly higher than that in patients with low expression of miR-155(P<0.05),and the 3-year non-progression-free survival rate(29.2%)and the overall survival rate(40.3%)of the miR-155 high-expression group were significantly lower than that of the miR-155 lower-expression group(81.3%and 83.3%)(P<0.05).The single-factor and multi-factor analysis results showed that the miR-155 expression level is the influencing factor of the progression-free survival and overall survival of the DLBCL.The healing rate of scratches in the low expression group of miR-155(0.53±0.04)was significantly lower than that in the control group(1.00±0.03)(P<0.05).The absorbance of cells in the low expression group of miR-155 was significantly lower than that in the control group on the 3rd and 4th day after culture(0.38±0.01 vs 0.56±0.03,0.56±0.02 vs 0.76±0.02)(P<0.05).Conclusion:The expression level of miR-155 in patients with diffuse large B-cell lymphoma significantly affects the prognosis of the patients,and the possible mechanism is that it can affect the prognosis of patients with diffuse large B-cell lymphoma.The ability of proliferation and migra

关 键 词：MIR-155 弥漫性大B细胞淋巴瘤 预后 

分 类 号：R733.4[医药卫生—肿瘤]